Your browser is no longer supported. Please, upgrade your browser.
Settings
ADXS Advaxis, Inc. daily Stock Chart
ADXS [NASD]
Advaxis, Inc.
Index- P/E- EPS (ttm)-2.29 Insider Own2.90% Shs Outstand42.49M Perf Week-13.74%
Market Cap181.43M Forward P/E- EPS next Y-2.35 Insider Trans-0.20% Shs Float36.18M Perf Month-32.97%
Income-91.90M PEG- EPS next Q-0.55 Inst Own50.60% Short Float27.04% Perf Quarter-36.74%
Sales14.00M P/S12.96 EPS this Y-23.80% Inst Trans-8.88% Short Ratio15.53 Perf Half Y-47.09%
Book/sh1.83 P/B2.33 EPS next Y-5.40% ROA-64.50% Target Price21.50 Perf Year-60.46%
Cash/sh2.10 P/C2.03 EPS next 5Y- ROE-93.50% 52W Range4.24 - 12.66 Perf YTD-40.36%
Dividend- P/FCF- EPS past 5Y17.40% ROI-62.00% 52W High-68.56% Beta2.23
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low-6.13% ATR0.36
Employees90 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)23.23 Volatility7.51% 6.77%
OptionableYes Debt/Eq0.00 EPS Q/Q-67.50% Profit Margin- Rel Volume5.11 Prev Close4.27
ShortableYes LT Debt/Eq0.00 EarningsSep 14 Payout- Avg Volume629.99K Price3.98
Recom1.60 SMA20-31.74% SMA50-36.01% SMA200-47.85% Volume1,390,965 Change-6.79%
Aug-03-16Reiterated Barclays Overweight $15 → $20
Sep-22-15Initiated Barclays Overweight $40
Sep-11-15Initiated Guggenheim Buy $30
Jun-16-15Reiterated H.C. Wainwright Buy $25 → $30
May-15-15Initiated Jefferies Buy $27
May-14-15Initiated MLV & Co Buy $34
Oct-23-14Initiated H.C. Wainwright Buy $8
Feb-18-14Initiated Aegis Capital Buy $18
Feb-10-14Initiated Noble Financial Buy $12
Sep-21-17 09:05AM  Advaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-19-17 09:03AM  Two Abstracts Featuring Advaxis Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting Business Wire
Sep-18-17 09:02AM  Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference Business Wire
07:30AM  Corporate News Blog - EMA Grants Positive CHMP Opinion to Tesaros Ovarian Cancer Drug ACCESSWIRE
Sep-13-17 08:20AM  Today's Research Reports on Stocks to Watch: Advaxis and Heat Biologics ACCESSWIRE -11.31%
Sep-12-17 12:34PM  Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today Motley Fool -19.88%
Sep-11-17 09:39PM  Advaxis reports 3Q loss Associated Press -7.69%
04:01PM  Advaxis Reports Business Update and Third Quarter 2017 Results Business Wire
Sep-08-17 07:20PM  What Does Advaxis Incs (ADXS) Share Price Indicate? Simply Wall St.
Aug-02-17 08:59AM  Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival Business Wire
Jul-13-17 09:06AM  Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders Business Wire +5.52%
Jul-06-17 04:48PM  Advaxis CEO Daniel O'Connor resigns Reuters
04:30PM  Advaxis Announces Change in Leadership Business Wire
Jun-26-17 08:55AM  Advaxis Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 Business Wire
Jun-16-17 09:58AM  Advaxis Breaks Down From Key Support Levels Investopedia
08:00AM  Advaxis to Present at 2017 BIO International Convention Business Wire
Jun-15-17 12:54PM  ETFs with exposure to Advaxis, Inc. : June 15, 2017 Capital Cube -11.23%
Jun-14-17 08:00AM  Advaxis to Be Featured on Worldwide Business with kathy ireland® Business Wire -5.84%
Jun-13-17 12:30PM  Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day Business Wire -7.82%
Jun-09-17 08:00AM  Advaxis to Webcast Investor & Analyst Day 2017 Business Wire -5.36%
Jun-08-17 09:17AM  Update: Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available Business Wire
Jun-07-17 08:30AM  Advaxis to Present at Jefferies 2017 Global Healthcare Conference Business Wire
08:07AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : June 7, 2017 Capital Cube
05:01AM  Advaxis reports 2Q loss Associated Press
Jun-05-17 11:50AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Advaxis, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Jun-01-17 08:00AM  Synthetic Genomics Launches cGMP Suite for Pharmaceutical Quality Manufacturing of Synthetic DNA for Advaxis' Clinical Trials PR Newswire
May-30-17 09:29AM  Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration TheStreet.com
06:59AM  Advaxis and Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate ADXS-DUAL and Opdivo (nivolumab) in Metastatic Cervical Cancer Business Wire
05:17AM  How Two Biotechs Fell On Cancer Partnerships With Bristol-Myers Investor's Business Daily
May-18-17 08:00AM  Advaxis to Host Investor & Analyst Day on June 12 Business Wire +5.09%
May-15-17 09:03AM  Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac Business Wire
08:18AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : May 15, 2017 Capital Cube
May-05-17 10:00AM  Erin Andrews to Participate in Cervical Cancer Educational Forum Hosted by Sylvester Comprehensive Cancer Center and Gildas Club, Sponsored by Advaxis Business Wire
May-04-17 03:37PM  ETFs with exposure to Advaxis, Inc. : May 4, 2017 Capital Cube
Apr-28-17 04:32PM  Advaxis, Inc. Value Analysis (NASDAQ:ADXS) : April 28, 2017 Capital Cube
Apr-27-17 08:32AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : April 27, 2017 Capital Cube
08:00AM  Advaxis Recognized as One of New Jerseys Best Places to Work 2017 Business Wire
Apr-21-17 02:42PM  ETFs with exposure to Advaxis, Inc. : April 21, 2017 Capital Cube
Apr-19-17 08:00AM  Advaxis Appoints Anthony Lombardo as Chief Business Officer GlobeNewswire
Mar-27-17 03:47PM  ETFs with exposure to Advaxis, Inc. : March 27, 2017 Capital Cube
03:47PM  ETFs with exposure to Advaxis, Inc. : March 27, 2017
08:00AM  Advaxis Provides Phase 1 Data of Higher Dose Axalimogene Filolisbac GlobeNewswire
Mar-23-17 01:36PM  EMA Certification Paves Way for Advaxis Drug Investopedia
01:36PM  EMA Certification Paves Way for Advaxis Drug at Investopedia
08:00AM  EMA Certification Paves the Way for the MAA Submission for Axalimogene Filolisbac in Metastatic Cervical Cancer GlobeNewswire
Mar-22-17 09:22AM  Advaxis, Inc. :ADXS-US: Earnings Analysis: Q1, 2017 By the Numbers : March 22, 2017 Capital Cube
09:22AM  Advaxis, Inc. :ADXS-US: Earnings Analysis: Q1, 2017 By the Numbers : March 22, 2017
Mar-16-17 01:04PM  ADVAXIS, INC. Financials
Mar-15-17 07:00AM  Advaxis Presents Oral Late-breaking Data on Phase 2 GOG-0265 Study of Axalimogene Filolisbac at SGOs Annual Meeting on Womens Cancer GlobeNewswire
Mar-13-17 08:00AM  Advaxis to Present at the 2017 Barclays Global Healthcare Conference GlobeNewswire
Mar-10-17 07:48AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : March 10, 2017 Capital Cube
07:48AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : March 10, 2017
Mar-07-17 08:00AM  Advaxis Appoints Al Blunt, M.D., as its Vice President of Medical GlobeNewswire -8.65%
Mar-06-17 08:41AM  Advaxis stock jumps 10% after FDA okays clinical trials for Amgen-partnered cancer drug at MarketWatch
06:00AM  Advaxis Announces FDA Acceptance of IND for Groundbreaking Personalized Neoepitope Immunotherapy, ADXS-NEO GlobeNewswire
Mar-02-17 01:21PM  These 5 Stocks Under $10 Could Explode Up Soon
08:00AM  Advaxis to Host Research Reception at Society of Gynecologic Oncology Annual Meeting on Womens Cancer GlobeNewswire
Feb-28-17 10:31AM  Advaxis Inks Cancer Drug Deal with Sellas at Investopedia
Feb-27-17 08:00AM  Advaxis and SELLAS Announce Licensing Agreement for Development of WT1 Antigen-Targeting Immunotherapy PR Newswire +6.74%
Feb-06-17 08:00AM  Advaxis Announces First Patient Dosed in Global Phase 3 AIM2CERV Trial for High-risk, Locally Advanced Cervical Cancer GlobeNewswire
Jan-30-17 08:30AM  GOG-0265 Study in Metastatic Cervical Cancer Selected for Late-Breaking Data Presentation at the Society of Gynecologic Oncologys Annual Meeting on Womens Cancer GlobeNewswire
Jan-26-17 07:46AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : January 26, 2017
Jan-25-17 08:00AM  New Published Research Reveals that Cervical Cancer Mortality Rates May Be Significantly Higher in the United States than Previously Reported GlobeNewswire
Jan-13-17 10:43AM  Advaxis, Inc. Value Analysis (NASDAQ:ADXS) : January 13, 2017
Jan-12-17 07:19AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : January 12, 2017
Jan-09-17 08:31AM  ADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
08:00AM  Advaxis Provides 2017 Business Outlook GlobeNewswire
06:39AM  ADVAXIS, INC. Files SEC form 10-K, Annual Report
Dec-15-16 04:31PM  ADVAXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Dec-12-16 08:15AM  Discussion on Advaxis ADXS-NEO, ADXS-HOT Programs Held During the International Congress on Immunotherapies in Cancer GlobeNewswire
Dec-07-16 08:00AM  Advaxis to Present Data at ImVacS-Immunization and Vaccine Summit on Use of Detoxified Listeriolysin O (dtLLO) as an Effective Adjuvant in Vaccine Formulations GlobeNewswire
Dec-04-16 03:42PM  How Advaxis, Inc. (ADXS) Stacks Up Against Its Peers at Insider Monkey
Nov-22-16 07:15AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : November 22, 2016
Nov-18-16 11:35AM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc. Business Wire
Nov-15-16 08:00AM  Advaxis to Present at the Jefferies 2016 London Healthcare Conference GlobeNewswire
Nov-11-16 12:20PM  ETFs with exposure to Advaxis, Inc. : November 11, 2016
07:30AM  Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting GlobeNewswire
Nov-10-16 08:25AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : November 10, 2016
Oct-28-16 01:15PM  Lifshitz & Miller Law Firm Announces Investigation of Advaxis, Inc., Banc of California, Inc., Biogen Inc., Franklin Resources, Inc., Juniper Pharmaceuticals, Inc., Opus Bank, Taro Pharmaceutical Industries Ltd., and Tyson Foods, Inc. PR Newswire
Oct-27-16 02:28PM  Advaxis Cervical Cancer Drug Makes Progress (ADXS) at Investopedia
02:03PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc. - ADXS PR Newswire
Oct-24-16 12:01PM  ADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
08:28AM  Advaxis stock drops as much as 14% after company releases data from trial that was halted last year at MarketWatch
08:00AM  Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2 GlobeNewswire
Oct-21-16 01:33PM  Advaxis Cervical Cancer Study Continues (ADXS) at Investopedia
12:42PM  Advaxis Phase 1/2 Cancer Trial Proceeds (ADXS) at Investopedia
Oct-20-16 07:30AM  Advaxis Initiates Combination Portion of Phase 1/2 Study with Merck GlobeNewswire
Oct-13-16 01:48PM  Advaxis Cleared for $2.7 Million Tax Credit (ADXS) at Investopedia
08:00AM  Advaxis to Receive $2.5M through the New Jersey Economic Development Authority NOL Program GlobeNewswire
Oct-11-16 08:00AM  Advaxis Research Reception at SITC 2016 to Review Recent AXAL Highlights and the AXAL-Durvalumab Combination Poster GlobeNewswire -8.06%
Oct-10-16 05:40PM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc. Business Wire
Oct-06-16 08:00AM  Advaxis CSO Invited to Speak at Immune Profiling World Congress GlobeNewswire -7.23%
Oct-05-16 08:11AM  Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : October 5, 2016
Oct-03-16 04:39PM  ADVAXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
08:00AM  Advaxis Appoints Christopher Duke as Chief Operating Officer GlobeNewswire
Sep-28-16 11:10AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc. - ADXS Accesswire
Sep-26-16 03:45PM  Advaxis Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting GlobeNewswire
Sep-19-16 04:30PM  Advaxis to Present at the Aegis Annual Growth Conference GlobeNewswire
Sep-13-16 11:15AM  Advaxis, Inc. Value Analysis (NASDAQ:ADXS) : September 13, 2016 -5.54%
Sep-12-16 09:21AM  Advaxis, Inc. breached its 50 day moving average in a Bearish Manner : ADXS-US : September 12, 2016 +7.21%
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. Its lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. The company is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma. It has clinical trial collaboration agreements with Merck & Co., Inc. for the Phase I/II dose-escalation and safety study of ADXS31-142; and MedImmune, LLC to initiate a Phase I/II clinical study in the United States to evaluate MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor. The company also has a licensing agreement with Global BioPharma Inc.; co-development and commercialization agreement with Especificos Stendhal SA de CV; and collaboration agreement with Amgen Inc. for the development and commercialization of ADXS-NEO, a preclinical investigational cancer immunotherapy treatment that activates patient's immune system to respond against mutations or neoepitopes. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PETIT ROBERTChief Scientific OfficerMar 31Sale8.242,45420,221119,597Apr 03 04:38 PM
Bonstein SaraChief Financial OfficerDec 30Sale7.375,52040,682126,443Jan 03 05:28 PM
MCKEARN THOMAS JDirectorDec 20Sale8.0812,31699,51369,804Dec 21 05:30 PM
PETIT ROBERTChief Scientific OfficerNov 02Sale8.322,79723,271120,744Nov 02 04:41 PM
O'Connor DanielChief Executive OfficerNov 02Sale8.328,24068,557294,656Nov 02 04:40 PM
Mayes, Gregory T.Chief Business OfficerOct 25Sale8.2319,162157,703103,087Oct 26 04:30 PM